Adequan for Dogs: Everything Vets Wish You Knew

🐾💉

FDA · DailyMed NIH · PMC · PetMD · Verified U.S. Data

The complete, FDA-sourced guide to Adequan Canine: how it works, the exact dosing protocol, real side effects, who should not receive it, the kidney and death questions answered honestly, and how it compares to Librela.

Researched and written by BestiePaws.com™ — All information independently verified from FDA, DailyMed/NIH, and peer-reviewed sources

🔑 10 Key Things to Know About Adequan for Dogs

Adequan Canine (polysulfated glycosaminoglycan, PSGAG) is the only FDA-approved injectable disease-modifying osteoarthritis drug (DMOAD) for dogs in the United States, approved under NADA 141-038 on July 15, 1997. It is manufactured by American Regent, Inc., Animal Health in Shirley, NY. Unlike pain medications that only mask symptoms, Adequan works directly at the joint level — inhibiting cartilage-degrading enzymes, stimulating new cartilage components, reducing joint inflammation, and improving joint fluid quality. It is extracted from bovine tracheal cartilage, classifies as a synthetic heparinoid, requires a veterinary prescription, and is administered by intramuscular injection. Research shows 1 in 3 dogs suffer from arthritis, and untreated osteoarthritis has been associated with a shortened lifespan of approximately 11% — making early intervention with a disease-modifying drug like Adequan one of the most important conversations your vet can have with you. BestiePaws.com™ presents the complete picture, including the risks the label states plainly.

1
What is Adequan and what does it actually do for dogs? Adequan Canine is the only FDA-approved injectable DMOAD (disease-modifying osteoarthritis drug) for dogs — meaning it treats the disease itself, not just its symptoms. It works via four documented mechanisms: (1) incorporating into damaged cartilage matrix, (2) inhibiting enzymes that destroy cartilage, (3) producing anabolic (building) effects in joint and cartilage tissue, and (4) reducing joint inflammation.
A peer-reviewed PMC study (received April 7, 2025; published September 2025) confirmed: “In diseased joint tissue, PSGAG stimulates (1) its own incorporation into the cartilage matrix, (2) inhibition of catabolic enzymes, (3) anabolic effects in the synovial and cartilage tissue, and (4) anti-inflammatory effects.” The active ingredient — polysulfated glycosaminoglycan (PSGAG) — is a semi-synthetic compound derived from bovine tracheal cartilage. It is similar to glycosaminoglycans (GAGs) naturally present in healthy cartilage. Per petmd.com (updated Sept 25, 2025, vet-reviewed): “Adequan Canine works best when used proactively to prevent osteoarthritis from worsening.” The clinical trial in the FDA approval documents (DailyMed/NIH) demonstrated statistically significant improvement in range of motion and total orthopedic score over placebo in dogs with radiographically confirmed joint disease of hips, stifles, shoulders, hocks, and elbows.
2
What is the Adequan dosage for dogs? FDA-approved label dose: 2 mg per pound of body weight (= 4.4 mg/kg) by intramuscular injection, given twice weekly for up to 4 weeks — a maximum of 8 injections per initial series. Adequan reaches the joint within 2 hours. Improvement is typically seen within 2–4 weeks of the initial series.
The full FDA-approved dosing from DailyMed (NIH) is: “Administer twice weekly for up to 4 weeks (maximum of 8 injections)” at 2 mg/lb IM. The vial contains 100 mg/mL in a 5 mL preserved multi-dose vial. Once punctured, the vial must be used within 28 days and punctured no more than 10 times. After the initial loading series, many veterinarians implement maintenance dosing — typically monthly or every 1–4 weeks depending on clinical response, though some vets repeat the twice-weekly protocol every 6 months. Adequan should be given intramuscularly (into the muscle). Subcutaneous (under the skin) administration is technically off-label — while some veterinarians use this route for ease of home administration, Dr. Ashley Darby BVSc (Dogster, March 2025) notes that subcutaneous injections may be less effective than the labeled IM route. Always follow your veterinarian’s specific protocol for your individual dog.
3
What are the side effects of Adequan for dogs? In the FDA clinical efficacy trial (8 weeks, 24 treated dogs), adverse reactions occurred after only 2.1% of injections and included: transient pain at the injection site, transient diarrhea, and abnormal bleeding — all mild, self-limiting, and requiring no therapy interruption. Post-approval voluntary reporting: vomiting, anorexia, depression/lethargy, diarrhea. In some cases, death has been reported.
The DailyMed/NIH prescribing information states verbatim: “The following adverse events are based on voluntary, post-approval reporting. Not all adverse reactions are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The signs reported are listed in decreasing order of reporting frequency: Vomiting, anorexia, depression/lethargy, diarrhea. In some cases, death has been reported.” The phrase “death has been reported” appears in post-approval voluntary reporting — it does not mean death is a common outcome or that Adequan caused each reported death. Post-approval adverse event databases receive reports from many sources; causality is often unconfirmed. At the FDA-approved label dose in healthy dogs, petmd.com (Sept 2025) confirms: “Adequan Canine can have negative consequences on pets with known liver disease or kidney disease or if an overdose is administered. In healthy pets, its effect on the liver and kidneys is generally considered safe.”
4
Is Adequan hard on the kidneys? At the FDA-approved label dose in healthy dogs: Adequan is generally considered safe for the kidneys. However: the kidneys are the primary route for excreting Adequan from the body. At approximately 7 times the recommended dose, normal dogs developed enlarged kidneys in safety studies. Adequan must be used with caution in dogs with pre-existing kidney disease. Discuss with your vet if your dog has reduced kidney function.
The DailyMed/NIH prescribing information explicitly states: “Use with caution in dogs with renal or hepatic impairment.” VeterinaryPartner.com (VIN) confirms: “When doses of approximately seven times the recommended dose were used, normal dogs developed enlarged kidneys. Because of this, caution is recommended when using this product in patients with kidney disease.” The overdose safety study data in the FDA’s NADA documentation shows that the 50 mg/kg group (far above the 4.4 mg/kg label dose) had increased kidney weights, microscopic lesions in the proximal convoluted tubules, and increased liver markers. The 15 mg/kg group also had increased kidney weights. These findings were at doses many times the therapeutic label dose — but they explain why kidney impairment is a caution. Dr. Buzby (toegrips.com, Feb 2025) notes: “The kidneys are primarily responsible for excreting Adequan (removing it from the body), a process that could be hindered by kidney failure.” For dogs with normal kidney function, routine monitoring is generally not required, though your vet may recommend periodic bloodwork depending on your dog’s age and overall health status.
5
Did Adequan kill my dog — what does “death has been reported” mean? The “death has been reported” statement on Adequan’s label comes from the FDA’s post-approval voluntary adverse event reporting system — not from the controlled clinical trial. These reports are submitted voluntarily and do not establish that Adequan caused the deaths. Causality cannot be confirmed from these reports. In the controlled clinical trial, no deaths occurred in the Adequan treatment group at the approved dose.
This is one of the most distressing things dog owners encounter when researching Adequan — and the phrasing deserves a clear explanation. The FDA requires manufacturers to collect and report all adverse events submitted by veterinarians and pet owners after approval, regardless of whether causality is confirmed. The DailyMed label states explicitly: “It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data.” In the controlled FDA efficacy trial (51 dogs, 2 mg/lb twice weekly, 4 weeks), no deaths occurred in the Adequan-treated group. The overdose safety study (32 beagle dogs given doses of 5 mg/kg, 15 mg/kg, and 50 mg/kg) had one dog in the 50 mg/kg group euthanized due to a large hematoma — at approximately 11 times the recommended dose. If your dog experienced a serious event after Adequan, report it to American Regent at 1-888-354-4857 and to the FDA/CVM Safety Reporting Portal. Do not let fear of this label statement prevent a necessary conversation with your vet about a drug that genuinely helps millions of arthritic dogs.
6
How long can a dog stay on Adequan? Adequan Canine is designed and safe for long-term use. After the initial 8-injection loading series, most veterinarians implement maintenance dosing — typically once monthly, or every 1–4 weeks — continued indefinitely as long as the dog benefits and tolerates it well. There is no established maximum lifetime dose at the approved therapeutic level.
BestiePaws.com™ (June 2025) confirms: “Adequan Canine is designed for long-term use — not just a temporary bandage. Its role as a DMOAD (Disease-Modifying Osteoarthritis Drug) distinguishes it from symptomatic treatments. Unlike NSAIDs or short-acting pain relievers, Adequan doesn’t merely reduce pain; it helps preserve cartilage, improve joint fluid quality, and reduce inflammation at the structural level.” Dr. Buzby (toegrips.com, Feb 2025) states: “It is reassuring to know that Adequan injections are safe for long-term use in dogs.” The prescribing documentation notes that the protocol is to repeat when clinical signs reappear. Real-world experience supports this — a Lab owner in a Chewy review reported their dog receiving Adequan for 9+ years continuously starting at age 4, still mobile at age 13. To minimize injection site discomfort during long-term use, the injection site should be rotated each administration — right hind limb, then left, then shoulder muscles, etc.
7
Which is better — Adequan or Librela? They target different aspects of canine OA and are not direct substitutes: Adequan modifies the disease (protects and repairs cartilage, improves joint health). Librela (bedinvetmab) blocks pain signals directly via nerve growth factor (NGF) inhibition. Librela typically produces more dramatic and faster pain reduction. Adequan preserves what Librela cannot — the joint structure itself. Many vets use both together.
BestiePaws.com™ (June 2025) provides the clearest comparison: “Adequan — better for joint health. Librela — faster for pain. Can they be used together? Possibly, but safety data on combination use is limited. Veterinary discretion is critical.” Dr. Buzby (Feb 2025): “Librela cuts down on the number of pain signals that get to the brain — the end result can be a dramatic reduction in pain that is usually more significant than you would get with Adequan. However, Librela does not have any effect on the health of the joints themselves.” Librela requires only monthly subcutaneous injection vs. Adequan’s twice-weekly IM series (initial loading). Librela takes approximately 7 days to begin working; full effect at 30–60 days (greatpetcare.com). Adequan improvement typically appears within 2–4 weeks. Librela is not appropriate for dogs under 1 year, spinal pain, postoperative use, or breeding/pregnant/lactating dogs. At the label dose, neither drug significantly impacts the liver or kidneys — making both options suitable for senior dogs with pre-existing organ concerns (at vet’s discretion).
8
Who should NOT receive Adequan? Absolute contraindications: dogs with hypersensitivity to PSGAG; dogs with known or suspected bleeding disorders (PSGAG is a synthetic heparinoid with blood-thinning properties). Use with caution: dogs with kidney or liver disease. Not evaluated: breeding, pregnant, or lactating dogs. No age or breed restrictions for healthy dogs.
The DailyMed/NIH prescribing information states: “Do not use in dogs showing hypersensitivity to PSGAG. PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders.” This heparin-like property is critical — PSGAG shares some pharmacological characteristics with the blood thinner heparin, meaning it can prolong clotting time and reduce platelet activity. A dog with von Willebrand disease, hemophilia, active internal bleeding, or any diagnosed coagulopathy should not receive Adequan. For dogs on other medications that affect bleeding (NSAIDs, aspirin), discuss with your vet before starting. Liver disease is a caution because it can independently impair blood clotting ability, compounding the heparinoid effect. Safety in breeding, pregnant, and lactating dogs has not been evaluated in clinical trials — discuss risk vs. benefit with your vet before using in intact females who may be pregnant.
9
Is Adequan available at Costco, and do I need a prescription? Yes, Adequan requires a valid veterinary prescription by federal law — “Federal law restricts this drug to use by or on the order of a licensed veterinarian.” It is not a standard over-the-counter pet supply item at Costco. Online pharmacies (Chewy Rx, PetMeds, 1-800-PetMeds, Costco Pharmacy) can fill Adequan with a valid prescription from your vet. Costco Pharmacy can sometimes fill veterinary prescriptions at competitive prices with a valid Rx.
The DailyMed label states verbatim: “Federal law restricts this drug to use by or on the order of a licensed veterinarian.” Adequan Canine (100 mg/mL, 5 mL preserved multi-dose vials, available as 1-vial or 2-vial packages) can be filled at Chewy Rx, 1-800-PetMeds, VetRxDirect, and some Costco Pharmacy locations with a valid vet prescription. Comparing prices between your veterinarian’s in-clinic dispensing and online pharmacy options is reasonable — some owners report meaningful savings on the ongoing maintenance phase through online Rx pharmacies. A qualifying 8-dose series purchase (two 5 mL vials) may be eligible for a $20 rebate from the manufacturer. Store at controlled room temperature 68–77°F (20–25°C). Once a vial is punctured, it must be used within 28 days and punctured no more than 10 times — after that, discard. Properly dispose of used needles per federal, state, and local environmental laws.
10
What do long-term Adequan reviews say — does it really work? The FDA clinical trial showed statistically significant improvement in range of motion and total orthopedic score vs. placebo at the approved dose. PMC peer-reviewed literature confirms its four biological mechanisms. Real-world: Chewy reviews, owner reports, and veterinary experience over 25+ years of U.S. use consistently report improvement in mobility, stiffness, and comfort — typically beginning within 2–4 weeks of the initial series.
The FDA’s controlled clinical trial (DailyMed/NIH) documented statistically significant improvement in both range of motion and total orthopedic score at the end of the 4-week, 8-injection protocol compared to saline placebo — with joints evaluated including hips, stifles, shoulders, hocks, and elbows. A 2025 PMC open-access review (published September 2025) summarized decades of veterinary pharmacology: PSGAG “is rapidly distributed to diseased joint tissue after intramuscular administration” and has confirmed anabolic, anti-inflammatory, and enzyme-inhibiting effects in cartilage. Adequan works best in early- to mid-stage osteoarthritis — it cannot reverse irreversible cartilage loss that has already occurred, but it can meaningfully slow further progression. Owners who start Adequan when their dog first shows intermittent lameness or stiffness consistently report better long-term outcomes than those who wait until disease is advanced. Wikipedia/PSGAG notes: “While it can cause an increased risk of bleeding, it is relatively safe and has a high LD50.” The drug has been in continuous veterinary use since equine approval in 1984 and canine approval in 1997 — a track record of nearly 40 years.

Sources: FDA fda.gov / DailyMed NIH dailymed.nlm.nih.gov (NADA 141-038 July 15 1997; 2 mg/lb IM twice weekly 4 weeks 8 max; 100mg/mL 5mL vial; benzyl alcohol preservative; contraindications: hypersensitivity PSGAG + bleeding disorders; caution: renal/hepatic impairment; not evaluated: breeding/pregnant/lactating; no age/breed restrictions; adverse reactions 2.1% of injections in trial; post-approval: vomiting/anorexia/depression/diarrhea/death reported; overdose: 50mg/kg increased ALT/cholesterol/liver/kidney weights/platelet/PT; 15mg/kg increased cholesterol+kidney weights; one dog euthanized hematoma week 12; store 68–77°F; 28 days after puncture; max 10 punctures; American Regent Inc. Shirley NY 11967; 1-888-354-4857); PMC pmc.ncbi.nlm.nih.gov Sept 2025 (received Apr 7 2025; PSGAG 4 mechanisms: incorporation/inhibition/anabolic/anti-inflammatory; rapidly distributed to diseased joint tissue); petmd.com Sept 25 2025 vet-reviewed (DMOAD proactively treats disease; works best proactively early; kidney/liver generally safe healthy pets; caution kidney/liver disease; death reported post-approval; Poison Control 1-800-222-1222); dogster.com Mar 6 2025 Dr. Ashley Darby BVSc (SC off-label less effective than IM; all load-bearing joints benefit); toegrips.com Feb 10 2025 Dr. Julie Buzby integrative vet (safe long-term use; rotate injection sites; maintenance monthly to q1–4 weeks; Librela more dramatic pain vs Adequan; can use together vet discretion; kidneys excrete Adequan; liver disease impairs clotting); bestiepaws.com BestiePaws.com™ June 10 2025 (Adequan DMOAD joint health; Librela NGF pain; combination limited data; early intervention key); greatpetcare.com Mar 2024 Dr. Brittany Kleszynski DVM (1 in 3 dogs arthritis; untreated OA ~11% shortened lifespan; Adequan does not affect liver/kidneys; Librela 7 days onset peak 30–60 days monthly); veterinarypartner.vin.com (7× dose enlarged kidneys normal dogs); dailypaws.com Mar 2026 (improvement 2–4 weeks; no known drug interactions)

📊 Adequan Canine — Key Facts at a Glance

💉 FDA-Approved Dosing Protocol

2 mg/lb · Twice Weekly · 4 Weeks

Approved dose: 2 mg/lb (4.4 mg/kg) by IM injection, twice weekly for 4 weeks — maximum 8 injections per initial series. Reaches the joint within 2 hours. NADA 141-038, approved July 15, 1997. Manufactured by American Regent Inc. Requires a valid veterinarian prescription. No age or breed restrictions.

🐾 Dogs With Arthritis in the U.S.

1 in 3 Dogs

Research shows 1 in 3 dogs in the U.S. suffer from arthritis (greatpetcare.com, Dr. Kleszynski DVM 2024). Untreated osteoarthritis has been associated with a shortened lifespan of approximately 11%. Arthritis affects dogs of all ages, breeds, and sizes — not just seniors. Early intervention with a DMOAD like Adequan produces meaningfully better long-term outcomes.

🔬 Adverse Events in Clinical Trial

2.1% of Injections

In the FDA efficacy trial (24 treated dogs, 8 weeks), adverse reactions were reported after only 2.1% of injections: transient pain at injection site, transient diarrhea, and abnormal bleeding. All effects were mild and self-limiting — no therapy interruptions required. The most common post-approval voluntary reports: vomiting, anorexia, lethargy, diarrhea.

📅 Years in Continuous Veterinary Use

25+ Years

Adequan Canine has been FDA-approved and in continuous veterinary use since 1997 — over 25 years. The PSGAG active ingredient has been used in equine veterinary medicine since 1984. It remains the only FDA-approved injectable DMOAD for dogs in the United States. No equivalent OTC supplement has completed the same clinical trials.

Sources: FDA NADA 141-038 (July 15 1997; 2 mg/lb twice weekly 4 weeks 8 max; American Regent Inc.); DailyMed NIH (2.1% adverse reactions efficacy trial; mild self-limiting); greatpetcare.com Mar 2024 (1 in 3 dogs; ~11% shortened lifespan untreated OA); BestiePaws.com™ April 2026 (only FDA-approved injectable DMOAD dogs; PSGAG equine use since 1984)

🔬 Adequan Canine — What Vets Know That the Label Doesn’t Tell You

⚠️ Critical Safety Information — Read Before Starting Adequan

DO NOT use in dogs with bleeding disorders. Adequan’s active ingredient PSGAG is a synthetic heparinoid — it shares pharmacological properties with the blood thinner heparin and can prolong clotting time and reduce platelet count. Dogs with von Willebrand disease, hemophilia, or any suspected coagulopathy must not receive Adequan. Discuss with your vet before use if your dog takes NSAIDs, aspirin, or any other blood-thinning medication. Use with caution in dogs with kidney or liver disease. Always tell your vet about ALL medications and supplements your dog takes.

How Adequan Actually Works — The Four Mechanisms

DMOAD · DISEASE-MODIFYING

Adequan is classified as a DMOAD — disease-modifying osteoarthritis drug — because it changes the trajectory of joint disease, not just its symptoms. Per the 2025 PMC peer-reviewed review, PSGAG works via four confirmed pathways in diseased joint tissue: (1) It incorporates directly into the damaged cartilage matrix, replenishing the structural glycosaminoglycans that have been depleted by osteoarthritis. (2) It inhibits catabolic (breakdown) enzymes like metalloproteinases that progressively destroy cartilage. (3) It stimulates anabolic (building) effects in synovial and cartilage tissue — increasing production of collagen, hyaluronic acid, and proteoglycans. (4) It reduces joint inflammation. The result is an improvement in joint fluid quality (viscosity and volume), reduced inflammatory signaling, and a slowing of the cartilage degradation spiral that defines progressive OA.

🔬 Incorporates into damaged cartilage matrix 🚫 Inhibits cartilage-destroying enzymes 🏗️ Stimulates collagen + proteoglycan production 💧 Improves joint fluid quality and volume 🔥 Anti-inflammatory at the joint level 📋 PMC peer-reviewed Sept 2025

The Dosing Protocol — Loading Series and Long-Term Maintenance

2 mg/lb · IM · TWICE WEEKLY × 4 WEEKS

The FDA-approved protocol is 2 mg/lb (4.4 mg/kg) by intramuscular injection twice weekly for up to 4 weeks — 8 injections maximum per series. This is the loading protocol. After this series, most veterinarians continue with maintenance dosing when clinical signs return or worsen. Maintenance frequency varies by dog: some need monthly injections, others every 1–4 weeks, others a repeat of the full twice-weekly protocol every 6 months. The injection is usually given in the muscle of the hindquarter. Rotate injection sites with each administration to prevent localized inflammation. Adequan reaches the joint within 2 hours. Clinical improvement typically appears within 2–4 weeks of the initial series. The vial must be stored at 68–77°F (20–25°C) and used within 28 days of first puncture (maximum 10 punctures per vial).

💉 2 mg/lb IM — twice weekly — 4 weeks max ⏱️ Reaches joint within 2 hours 📅 Improvement typically 2–4 weeks 🔄 Rotate injection sites each dose 📦 Vial: use within 28 days; max 10 punctures 🌡️ Store 68–77°F (20–25°C)

Who Benefits Most — Early Stage Arthritis and Specific Joints

EARLY INTERVENTION · ALL SYNOVIAL JOINTS

Adequan works best when started early — before irreversible cartilage damage has occurred. It cannot reverse damage that has already happened, but it can significantly slow further progression. It benefits all load-bearing (synovial) joints: hips, knees (stifles), shoulders, elbows, hocks, and spine. The FDA clinical trial confirmed efficacy across hips, stifles, shoulders, hocks, and elbows. Because Adequan circulates systemically after IM injection, a dog with arthritis in multiple joints receives treatment to all of them simultaneously — unlike a joint injection that only helps one joint. It works best in combination with other multimodal approaches: weight management, low-impact exercise, joint supplements, NSAIDs or other pain management, and physical therapy.

✅ Works best in early-to-mid stage OA 🦴 Hips, stifles, shoulders, elbows, hocks 🔄 Systemic — treats all joints simultaneously ⚠️ Cannot reverse irreversible damage 💊 Best combined with NSAIDs + supplements

Adequan vs. Librela — The Complete Honest Comparison

ADEQUAN = DMOAD · LIBRELA = PAIN BLOCKER

These are fundamentally different drugs that target different aspects of OA. Adequan is a disease-modifying drug (DMOAD) — it protects and repairs joint cartilage and slows disease progression but does not provide direct pain blocking. Librela (bedinvetmab) is an anti-nerve growth factor monoclonal antibody — it directly blocks pain signals at the neurological level but does not modify the underlying joint disease. Librela produces more dramatic and faster pain relief than Adequan. Adequan preserves the joint structure that Librela cannot. Many vets now use both together as part of a multimodal plan. Neither significantly impacts liver or kidneys at label doses — both are suitable for senior dogs and those with pre-existing organ concerns at vet discretion. Librela: monthly subcutaneous injection; onset 7 days; peak 30–60 days. Not for dogs under 1 year, spinal pain, or breeding/pregnant females.

🦴 Adequan: modifies disease; protects cartilage 💊 Librela: blocks pain signals (NGF inhibitor) ⚡ Librela: more dramatic pain relief 🏗️ Adequan: preserves joint structure ✅ Can be used together (vet discretion) 📅 Librela: monthly SQ; onset 7 days

The Kidney, Liver, and Bleeding Risk — What the Science Actually Shows

HEPARINOID · RENAL EXCRETION · CAUTION GROUPS

Three safety facts every Adequan owner should understand. (1) HEPARINOID RISK: PSGAG is pharmacologically similar to heparin (a blood thinner). It can prolong clotting time and reduce platelet count — which is why dogs with bleeding disorders are contraindicated. At approved doses this effect is mild, but it matters for surgical planning, dogs on NSAIDs, and any dog with a suspected coagulopathy. (2) KIDNEY CAUTION: The kidneys excrete Adequan. At 7 times the recommended dose, normal dogs developed enlarged kidneys. At approved doses in healthy dogs, kidney effects are not clinically significant — but dogs with pre-existing kidney disease may not clear the drug efficiently, making accumulation possible. (3) LIVER CAUTION: Liver disease can independently impair clotting, compounding the heparinoid effect. Use with caution in hepatic impairment. ALT elevation was only observed at the 50 mg/kg overdose level in safety studies — not at the therapeutic 2 mg/lb dose.

⚠️ Heparinoid: prolongs clotting time + reduces platelets 🚫 DO NOT use: bleeding disorders 🫘 Kidneys: primary excretion route ⚠️ Caution: kidney OR liver disease ✅ Safe at label dose in healthy dogs (petmd.com) 📞 Adverse events: 1-888-354-4857

Can Owners Give Adequan Injections at Home?

IM LABELED · SQ OFF-LABEL · OWNER TRAINING

Many veterinarians teach owners to administer Adequan at home — particularly for the long-term maintenance phase. The labeled route is intramuscular (IM), but some veterinarians prescribe subcutaneous (under-the-skin) injections as an off-label convenience. Dr. Ashley Darby BVSc (Dogster, March 2025) notes that subcutaneous injections may be less effective than the IM route. If your vet shows you how to give injections at home, you will also need syringes and needles — 22-gauge, 3/4 to 1-inch needles are commonly used. Proper needle disposal in a sharps container is required by law in most states. Never share needles between doses. Each vial can be punctured a maximum of 10 times and must be discarded 28 days after first puncture — set a reminder on your phone or mark the vial with the date of first use.

🏠 Home injection possible with vet training 💉 Labeled route: IM (intramuscular) ⚠️ SQ (subcutaneous) = off-label; may be less effective 🗓️ Mark vial: 28-day discard + 10-puncture max 🗑️ Sharps container for needle disposal (required)

OTC Supplements vs. Adequan — Why They Are Not the Same

ONLY FDA-APPROVED INJECTABLE DMOAD

Glucosamine, chondroitin sulfate, omega-3 fish oil, and other joint supplements are widely available and may provide supportive benefit — but they have not completed the same clinical trials as Adequan and are not classified as drugs. Chewy’s prescribing information states: “There are many supplements and over-the-counter products making similar claims to Adequan Canine. However, these products are only supported by statements and do not have the product testing and trials Adequan Canine completed to obtain FDA approval.” The key difference: FDA drug approval requires demonstrating both safety and efficacy through controlled trials before a product can make treatment claims. OTC supplements are regulated as animal feeds, not drugs, and are not required to demonstrate efficacy. Supplements are best used alongside Adequan, not instead of it.

✅ Adequan: only FDA-approved injectable DMOAD ⚠️ OTC supplements: no FDA drug efficacy requirement 🤝 Supplements: supportive alongside Adequan 📋 FDA approval = controlled safety + efficacy trials 🌐 adequancanine.com (prescribing info)

Adequan as Part of a Multimodal Arthritis Plan

DMOAD + NSAID + PHYSICAL THERAPY + WEIGHT MGMT

Adequan is most effective when used as part of a multimodal (multiple-approach) arthritis management plan. Dr. Leilani Alvarez (Head of Integrative & Rehabilitative Medicine, NYC’s Schwarzman Animal Medical Center) lists Adequan alongside NSAIDs, gabapentin, amantadine, CBD/CBDA, joint injections, and acupuncture as complementary pain management tools. Other components of a complete OA plan: weight management (every extra pound accelerates joint wear), low-impact daily exercise (at least 60 minutes walking per day, swimming, rehabilitation exercises), prescription therapeutic diets if overweight, laser therapy, and physical rehabilitation including massage, range-of-motion exercises, and targeted strength work. Adequan’s unique contribution: slowing disease progression at the cartilage level — a role no pain medication, supplement, or physical modality can replicate.

💊 Combine with NSAIDs for pain (carprofen, etc.) 🏋️ Physical therapy + low-impact exercise ⚖️ Weight management: critical 🪡 Acupuncture + laser as adjuncts 🌐 AKC: Dr. Alvarez, Schwarzman AMC NYC

Sources: PMC pmc.ncbi.nlm.nih.gov Sept 2025 (4 PSGAG mechanisms: incorporation/enzyme inhibition/anabolic/anti-inflammatory; rapidly distributed diseased joint tissue IM); DailyMed NIH / FDA NADA 141-038 (2 mg/lb IM twice weekly 4 weeks 8 max; 100mg/mL; heparinoid contraindication bleeding disorders; caution renal/hepatic; reaches joint 2 hours; 28-day puncture; max 10 punctures; store 68–77°F; overdose: 50mg/kg enlarged kidneys ALT cholesterol prothrombin PT platelets; 15mg/kg cholesterol+kidney weights; hematoma 50mg/kg week 12); petmd.com Sept 2025 (DMOAD; early use best; kidney/liver safe healthy pets; caution kidney/liver disease); dogster.com Mar 2025 Dr. Darby BVSc (SQ off-label less effective IM; all synovial joints benefit); toegrips.com Feb 2025 Dr. Buzby (long-term safe; rotate sites; maintenance monthly q1–4wk; kidneys excrete; liver clotting risk; Librela more dramatic pain; can use together); bestiepaws.com BestiePaws.com™ June 2025 (Adequan DMOAD joint health; Librela NGF pain; early intervention key; combination limited safety data); greatpetcare.com Mar 2024 Dr. Kleszynski DVM (1 in 3 dogs; ~11% shorter lifespan untreated; liver/kidneys safe label dose; Librela 7 days onset 30–60 days peak monthly); veterinarypartner.vin.com (7× dose enlarged kidneys); dailypaws.com Mar 2026 (improvement 2–4 weeks; no known drug interactions); chewy.com Rx (only FDA-approved injectable DMOAD; OTC supplements lack FDA trials; $20 rebate 8-dose series); AKC akc.org Dr. Alvarez Schwarzman AMC (Adequan listed multimodal; not for spinal pain/<1yr — Librela); wikipedia PSGAG (high LD50; increased bleeding risk; relatively safe)

❓ Adequan Questions Answered Plainly

💡 How Long Can a Dog Stay on Adequan?

Adequan Canine is designed for long-term use — there is no established maximum duration at the approved therapeutic dose in healthy dogs. After the initial loading series (8 injections over 4 weeks), most veterinarians continue with maintenance dosing when clinical signs return or worsen. Maintenance protocols vary: some dogs receive monthly injections; others receive injections every 1–4 weeks; some vets repeat the full twice-weekly series every 6 months. BestiePaws.com™ (June 2025) confirms: “After the initial loading dose (2 injections per week for up to 4 weeks), many veterinarians implement maintenance dosing, which may involve once-monthly or quarterly injections depending on clinical response.” Dr. Buzby (Feb 2025): “Since Adequan is so useful in slowing the progression of osteoarthritis, it is reassuring to know that Adequan injections are safe for long-term use in dogs.” Real-world owner reports document dogs receiving Adequan continuously for 9–10+ years with maintained mobility and no significant side effects. To minimize injection site reactions during long-term use, rotate the injection site each administration. Dogs on long-term Adequan may benefit from periodic veterinary examinations and occasional bloodwork depending on their age and overall health, though no specific monitoring is formally required by the prescribing information.

💡 What Are the Negative Side Effects of Adequan?

At the FDA-approved dose, side effects are uncommon. In the controlled clinical trial, adverse reactions were reported after only 2.1% of injections in the Adequan treatment group — transient pain at the injection site (1 incident), transient diarrhea (2 dogs), and abnormal bleeding (1 incident). All were mild and self-limiting. Post-approval voluntary reports — which include all reports submitted regardless of confirmed causality — list, in decreasing order of frequency: vomiting, anorexia, depression/lethargy, diarrhea, and in some cases, death. The death reports are post-approval voluntary data, not confirmed Adequan-caused deaths; causality cannot be established from these reports. At overdose levels (7–11× the recommended dose), enlarged kidneys, liver enzyme changes, and prolonged clotting time were documented in safety studies. In healthy dogs at label dose: petmd.com (Sept 2025) confirms the liver and kidneys are generally considered safe. Key risk groups: dogs with bleeding disorders (contraindicated); dogs with kidney or liver disease (use with caution); breeding, pregnant, or lactating dogs (not evaluated — discuss with vet). If your dog experiences vomiting, unexpected bleeding, injection site swelling, or any neurological signs after Adequan, contact your veterinarian and report the event to American Regent at 1-888-354-4857.

💡 Which Is Better — Adequan or Librela?

They are not directly comparable — they target fundamentally different aspects of canine osteoarthritis. Adequan (PSGAG) is a disease-modifying osteoarthritis drug (DMOAD): it inhibits cartilage-destroying enzymes, stimulates new cartilage components, and improves joint fluid — directly protecting the joint structure itself. It does not provide direct, fast pain relief — its benefit to comfort comes through improving joint health over weeks. Librela (bedinvetmab) is an anti-nerve growth factor monoclonal antibody: it blocks NGF-mediated pain signaling, providing faster and often more dramatic pain relief than Adequan. But it does not modify the joint disease at all — it only manages the pain. Dr. Buzby (Feb 2025): “Librela cuts down on the number of pain signals that get to the brain — the end result can be a dramatic reduction in pain that is usually more significant than you would get with Adequan. However, Librela does not have any effect on the health of the joints themselves.” For the majority of arthritic dogs, BestiePaws.com™ recommends discussing both with your veterinarian as complementary therapies — Adequan for disease modification, Librela for pain management — as part of a multimodal plan. Limitations of Librela: not appropriate for dogs under 1 year old; not evaluated in spinal pain; not for breeding/pregnant females; monthly subcutaneous injection required indefinitely.

💡 Is Adequan Hard on the Kidneys — and Did It Kill My Dog?

Kidney question: At the FDA-approved dose in dogs with healthy kidneys, Adequan is generally considered safe for the kidneys (petmd.com, Sept 2025). The kidneys are the primary route for excreting Adequan — meaning in dogs with reduced kidney function, the drug may not clear efficiently and could accumulate. The prescribing information explicitly states “use with caution in dogs with renal impairment.” At 7 times the recommended dose in safety studies, normal dogs developed enlarged kidneys — which is why this caution exists. For dogs with normal kidney function, no routine kidney monitoring is formally required, though your vet may recommend bloodwork periodically based on your dog’s age. Death question: The Adequan label states “in some cases, death has been reported” — this comes from the FDA’s post-approval voluntary adverse event database, which collects all reports submitted regardless of causality. The DailyMed label explicitly acknowledges: “It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data.” In the controlled clinical trial at the approved dose, no deaths occurred in the Adequan treatment group. If you believe Adequan contributed to your dog’s death or serious illness, report to American Regent at 1-888-354-4857 and to the FDA Safety Reporting Portal. Your report helps build the post-market safety data that protects all dogs.

Sources: DailyMed NIH (2.1% adverse reactions trial; post-approval voluntary: vomiting/anorexia/lethargy/diarrhea/death reported; causal relationship cannot be confirmed; post-approval voluntary data; caution renal/hepatic; not evaluated breeding/pregnant/lactating); petmd.com Sept 2025 (liver/kidneys generally safe healthy pets; caution kidney/liver disease); toegrips.com Feb 2025 Dr. Buzby (safe long-term use; Librela more dramatic pain; kidneys excrete Adequan); bestiepaws.com BestiePaws.com™ June 2025 (Adequan DMOAD joint health; Librela NGF pain; combination possible; early intervention key); veterinarypartner.vin.com (7× dose enlarged kidneys; caution kidney disease); akc.org Dr. Alvarez Schwarzman AMC NYC (Librela not for dogs <1yr; not for spinal pain; monthly SQ); greatpetcare.com (Librela 7-day onset; peak 30–60 days; monthly); American Regent 1-888-354-4857 adverse event reporting

✅ Five Things BestiePaws.com™ Recommends Before Starting Adequan

Tell your vet about every medication and supplement your dog takes — especially NSAIDs, aspirin, or any drug affecting clotting. Adequan is a synthetic heparinoid with blood-thinning properties. The combination with other anticoagulant or anti-inflammatory medications requires veterinary evaluation. There are no known formal drug interactions listed in the prescribing information, but combinations affecting bleeding risk require individual assessment.
Request a baseline bloodwork panel if your dog is a senior or has any kidney or liver concerns. Adequan is excreted by the kidneys. Pre-treatment bloodwork establishes a baseline for kidney and liver function values — so if any changes occur during treatment, they are detectable and attributable. This is especially important for dogs over 8 years old or those with any prior organ impairment.
Start Adequan early — not as a last resort. The single biggest mistake with Adequan is waiting too long. It cannot reverse cartilage that has already been destroyed; it can only protect what remains. Dogs started on Adequan when arthritis is first confirmed — even if they are only mildly lame — consistently show better long-term outcomes than dogs started in advanced stages. If your vet mentions arthritis at a routine exam, ask about Adequan that day.
Learn the injection technique if you plan to administer at home. Ask your veterinarian or vet tech to demonstrate IM injection technique before attempting it yourself. Use a 22-gauge, 3/4 to 1-inch needle in a rotating site pattern (right hindquarter → left hindquarter → shoulder muscles, etc.). Mark the vial with the date of first puncture — it must be discarded within 28 days and after a maximum of 10 punctures. Store at 68–77°F. Never re-use needles. Dispose of sharps in a puncture-proof container.
Know what to watch for and who to call. Expected: mild stiffness or soreness at the injection site for 12–24 hours after each dose. Not expected: visible swelling, hematoma, unexpected bleeding, vomiting, complete loss of appetite lasting more than 24 hours, or significant lethargy. Contact your veterinarian immediately if any unexpected signs develop. Report serious adverse events to American Regent (1-888-354-4857) and the FDA Safety Reporting Portal (safetyreporting.hhs.gov). Human accidental injection: call Poison Control immediately at 1-800-222-1222.

📋 Key Resources — Save These: 🌐 Prescribing info: adequancanine.com 🌐 DailyMed label: dailymed.nlm.nih.gov 🌐 FDA approval: animaldrugsatfda.fda.gov 📞 American Regent adverse events: 1-888-354-4857 📞 FDA Safety Reporting: safetyreporting.hhs.gov 📞 Poison Control (accidental human): 1-800-222-1222 🌐 PMC peer-reviewed research: pmc.ncbi.nlm.nih.gov 🌐 BestiePaws.com™

This guide is independently researched and written by BestiePaws.com™ for informational purposes only. BestiePaws.com™ is not affiliated with, compensated by, or endorsed by American Regent, Inc., Zoetis, or any other manufacturer. This content does not constitute veterinary medical advice. Always consult a licensed veterinarian before starting, changing, or stopping any medication for your dog. Adequan® Canine is a registered trademark of American Regent, Inc. Librela® is a registered trademark of Zoetis Services LLC. All other product names are the property of their respective owners.

Primary sources: FDA fda.gov / animaldrugsatfda.fda.gov (NADA 141-038 July 15 1997; Freedom of Information Summary); DailyMed NIH dailymed.nlm.nih.gov (full prescribing information: PSGAG 100mg/mL; American Regent Inc. Shirley NY 11967; 1-888-354-4857; 2 mg/lb IM twice weekly 4 weeks 8 max; no age/breed restrictions; benzyl alcohol preservative; heparinoid: DO NOT use bleeding disorders; caution renal/hepatic; not evaluated breeding/pregnant/lactating; adverse reactions trial 2.1%; post-approval: vomiting/anorexia/depression/diarrhea/death voluntary reporting; overdose 50mg/kg: ALT/cholesterol/platelets/PT/liver/kidney weights; hematoma euthanized week 12; 15mg/kg: cholesterol+kidney weights; store 68–77°F; 28-day first puncture; max 10 punctures); PMC pmc.ncbi.nlm.nih.gov/articles/PMC12587828 (Open Access received Apr 7 2025 revised Aug 10 2025 accepted Aug 25 2025 published Sept 2025: 4 PSGAG mechanisms confirmed; rapidly distributed diseased joint tissue after IM; bovine tracheal cartilage; MW 3000–15000 Da); petmd.com updated Sept 25 2025 vet-reviewed (DMOAD proactively treats disease; early use; kidney/liver generally safe healthy pets at label dose; caution kidney/liver disease; death reported post-approval voluntary; 1-800-222-1222 Poison Control); dogster.com Mar 6 2025 Dr. Ashley Darby BVSc (SQ off-label less effective IM; circulates all load-bearing synovial joints); toegrips.com Feb 10 2025 Dr. Julie Buzby integrative vet (safe long-term; rotate injection sites; maintenance monthly to q1–4wk; Librela more dramatic pain relief; Librela does not modify joints; can use together vet discretion; kidneys excrete; liver disease clotting); bestiepaws.com BestiePaws.com™ June 10 2025 (Adequan DMOAD joint health Librela NGF pain; combination possible limited data; early intervention key; BestiePaws.com™ trademark); greatpetcare.com Mar 2024 Dr. Brittany Kleszynski DVM updated Jun 2025 (1 in 3 dogs arthritis; untreated OA ~11% shortened lifespan; Adequan safe liver/kidneys; Librela first anti-NGF mAb; 7 days onset; peak 30–60 days; monthly SQ); veterinarypartner.vin.com (7× dose enlarged kidneys; caution kidney disease); dailypaws.com Mar 2026 (improvement 2–4 weeks; no known drug interactions; 22-gauge needle IM); chewy.com (only FDA-approved injectable DMOAD; OTC supplements lack FDA trials; $20 rebate 8-dose series; reaches joint 2 hours); akc.org Oct 2025 (Dr. Leilani Alvarez Head Integrative+Rehab Medicine Schwarzman AMC NYC; Librela: NOT for dogs <1yr; NOT for spinal pain; NOT postoperative; monthly SQ; 7–10 days onset; Dr. Sharon Campbell Zoetis); wikipedia PSGAG Sept 2025 (injectable drug; high LD50; relatively safe; increased bleeding risk; some conflicting efficacy results in literature)

Dog Medicine

Recommended Reads

Leave a Reply Cancel reply